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Abstract: Adjuvant chemotherapy reduces risk of relapse and cancer-related mortality in early 
stage breast cancer. Over the last decade, taxanes (paclitaxel and docetaxel) have been incorpo-
rated into various adjuvant trials and have demonstrated a signiﬁ  cant beneﬁ  t in the management 
of early stage breast cancer. Clinical trials using combinations of taxanes with targeted therapy 
have also shown considerable activity in breast cancer. This article reviews the pharmacology 
of docetaxel, a semi-synthetic taxane, and the clinical trials supporting its use in patients with 
node-positive breast cancer.
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Introduction
Nodal involvement is one of the major determinants of the risk of relapse in early stage 
breast cancer. Adjuvant polychemotherapy improves disease-free and overall survival 
in early breast cancer. The addition of paclitaxel to standard anthracycline regimen 
resulted in further improvement in disease-free and overall survival in node-positive 
patients (Henderson et al 2003) leading to its approval in the management of early 
stage breast cancer. The key advantage of taxanes is its noninterference with the phar-
macokinetics of anthracyclines and its efﬁ  cacy in anthracyclines-resistant disease.
Docetaxel is an antineoplastic agent belonging to the taxoid family with activity 
against a wide range of human malignancies (Bridgewater 2004). It is a semi-synthetic 
agent derived from a European yew tree, Taxus baccata, and was ﬁ  rst identiﬁ  ed as an 
alternative to paclitaxel in 1986 (Bissery et al 1995). Its chemical structure differs from 
paclitaxel with a hydroxyl group replacing the acetyl group at C-10 and variations at 
the C-13 side chain (Ringel and Horwitz 1991). These structural modiﬁ  cations confer 
enhanced solubility in aqueous solution, and clinical studies have shown that docetaxel 
may be active in metastatic cancers resistant to paclitaxel (Valero et al 1998; Michaud 
et al 2000; Verschraegen et al 2000).
The current recommended dose for docetaxel is 60–100 mg/m2 given as a 1-hour 
infusion every 3 weeks. Although initially approved in 1996 for treatment of anthracy-
cline-refractory metastatic breast cancer, docetaxel is now also approved as adjuvant 
therapy in the management of early, high-risk breast cancer (Ravdin et al 1995; Valero 
et al 1995). This review will discuss the dosing and toxicity proﬁ  le of docetaxel and 
the studies utilizing docetaxel in patients with node-positive breast cancer.
Mechanism of action
Docetaxel acts by binding to the beta-tubulin subunit of the microtubules, which causes 
stabilization of tubulin polymerization, resulting in cell cycle arrest at G2/M phase and 
inhibition of mitosis (Eisenhauer and Vermorken 1998). Microtubules are the backbone 
of the cellular skeleton that is essential for the maintenance of cell shape, intracel-
lular transport, reproduction, and neurotransmission. Docetaxel has a high afﬁ  nity for Therapeutics and Clinical Risk Management 2008:4(2) 420
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this site, approximately 1.9-fold that of paclitaxel, targeting 
the centrosome organization and acting on the cell during 
S/G2/M phase. Stabilization of the microtubules disrupts the 
dynamic reorganization of the microtubules into spindles 
resulting in formation of abnormal bundles, which inhibit cell 
proliferation leading to cell death (Rinel and Horwitz 1991; 
Diaz and Andreu 1993). Compared with paclitaxel, there 
is a greater uptake of docetaxel into the tumor and slower 
efﬂ  ux out of tumor cells, resulting in higher exposure of the 
tumor cells to docetaxel. This could explain the activity of 
docetaxel in paclitaxel-resistant tumors.
Toxicity
Neutropenia is the principal toxicity of docetaxel (Schrijvers 
et al 1993; Cortes and Pazdur 1995) and has led to dose reduc-
tion and use of growth factors in patients with node-positive 
breast cancer. At a dose of 100 mg/m2, grade 4 neutropenia 
(500 cells/mm2) occurs in 85% of patients. The most 
important determinant of neutropenia is the extent of prior 
therapy. Despite being formulated in polysorbate 80, hyper-
sensitivity reactions have been reported in approximately 
31% of patients receiving docetaxel without premedications 
(Schrijvers et al 1993; Cortes and Pazdur 1995). The current 
recommendation is to give dexamethasone 8 mg twice a day 
for 3 days, starting a day prior to administration of docetaxel 
with or without H1 and H2 receptor antagonists given 30 min-
utes before docetaxel (Piccart et al 1997; Markman 2003). 
This regimen also reduces the incidence of the unique ﬂ  uid 
retention syndrome characterized by edema, weight gain, and 
third-space ﬂ  uid collection caused by docetaxel. Evidence 
indicates that this is due to capillary leak and is usually not 
apparent until a cumulative dose of 400 mg/m2 is reached. 
Although ﬂ  uid retention is reversible, it takes several months 
to resolve after discontinuation of docetaxel (Piccart et al 
1997). Patients developing progressive peripheral edema 
may be treated with diuretics for symptom relief.
Skin toxicity may occur in as many as 50%–75% of 
patients (Schrijvers et al 1993; Markman 2003). The most 
common is an erythematous, pruritic, maculopapular rash 
that affects the forearm, hands, and feet; premedication 
reduces its incidence. The other less common cutaneous 
reactions include palmar-plantar erythrodysesthesia and ony-
chodystrophy characterized by brown discoloration, ridging, 
onycholysis, and, in extreme cases, loss of nail plate. Mild 
to moderate peripheral neuropathy manifesting as paras-
thesia, dysesthesia, and pain occurs in approximately 40% 
of patients with no prior treatment. Patients with a history 
of prior cisplatin therapy or alcohol abuse are particularly 
susceptible (Zimmerman et al 1994, 1995; Piccart et al 1997; 
Hainsworth et al 1999).
Stomatitis appears to be more frequent with docetaxel 
than paclitaxel. Hyperlacrimation, although initially classi-
ﬁ  ed as an unexpected side effect, is now being increasingly 
reported. This excessive tearing resulting from cannalicu-
lar/nasolacrimal duct stenosis can lead to difﬁ  culty reading 
and driving, and it can affect quality of life (Esmaeli et al 
2001). Interventions such as temporary silicone intubation 
and dacryocystorhinostomy with placement of silicone or 
pyrex tube may be needed to relieve symptoms (Esmaeli 
2005). Severe gastrointestinal side effects are typically rare, 
although nausea, vomiting, and diarrhea may occur.
Docetaxel in node-positive 
breast cancer
The Breast Cancer International Research Group (BCIRG) 
001 (Martin et al 2005) adjuvant study randomly allocated 
1491 patients with node-positive breast cancer to docetaxel 
(75 mg/m2), doxorubicin, and cyclophosphamide (TAC) or 
to ﬂ  uorouracil, doxorubicin, and cyclophosphamide (FAC) 
for 6 cycles (Figure 1). At a median follow-up of 55 months, 
there was a 26% reduction in the risk of recurrence (hazard 
ratio [HR] = 0.74; 95% conﬁ  dence interval (CI) = 0.60–0.92; 
p = 0.0047) in the docetaxel arm. Longer disease-free survival 
(DFS) was seen in the docetaxel group regardless of the 
estrogen receptor/progesterone receptor status. This resulted 
in a beneﬁ  t in overall survival (OS) for TAC (87% vs 81%; 
p = 0.008) (46) (Table 1). Subgroup analysis showed that 
patients with fewer than 3 axillary nodes derived a more 
signiﬁ  cant beneﬁ  t from the addition of docetaxel in terms 
of DFS (90% vs 79%, p = 0.0002) and OS (96% vs 89%; 
p = 0.006). The incidence of grade 3 or 4 neutropenia (65.5% 
vs 49.3%, p  0.001) and febrile neutropenia (24.7% vs 
2.5%, p  0.001) was higher in the TAC group. Though 
grade 3 or 4 infections occurred in 3.9% of patients treated 
with TAC and 2.2% of those treated with FAC (p = 0.05), 
the rates of sepsis did not differ between the two groups. 
The investigators concluded that TAC is superior to FAC in 
node-positive breast cancer patients.
Voegl et al (2004) in a subanalysis of the BCIRG 001 
trial investigated the role of growth factor support following 
neutropenic events. Granulocyte colony stimulating factor 
(G-CSF) was used as secondary prophylaxis for 87% (TAC) 
and 44% (FAC) patients. The rate of febrile neutropenia per 
cycle among patients receiving TAC dropped to 3.1% and 
FAC to 0.5% after growth factor support. This retrospective 
subgroup analysis demonstrated a higher rate of neutropenic Therapeutics and Clinical Risk Management 2008:4(2) 421
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fevers in patients on the TAC regimen, and that prophylaxis 
with G-CSF after the ﬁ  rst episode can decrease the incidence 
of neutropenic complications.
Combination or sequential docetaxel was compared with 
a nontaxane regimen in 2887 patients with node-positive 
breast cancer (Crown et al 2006). Patients were randomized 
to 4 arms: 4 cycles of doxorubicin (A) (75 mg/m2) fol-
lowed by 3 cycles of cyclophosphamide, methotrexate, and 
5-ﬂ  uorouracil (CMF), 4 cycles of doxorubicin and cyclo-
phosphamide (AC) followed by 3 cycles of CMF, 3 cycles 
of doxorubicin followed by 3 cycles of docetaxel (T) (100 
mg/m2) followed by 3 cycles of CMF, or, ﬁ  nally, 4 cycles 
of doxorubicin (50 mg/m2) and docetaxel (75 mg/m2) 
followed by 3 cycles of CMF. The primary end-point of 
the study was DFS. The A→T→CMF arm demonstrated 
a signiﬁ  cantly improved DFS over the AT→CMF (p = 0.047) 
and A→CMF (p = 0.035) arms.
The French FNCLCC-PACS 01 trial randomly assigned 
1999 patients with node-positive breast cancer to 6 cycles 
of ﬂ  uorouracil 500 mg/m2, epirubicin 100 mg/m2, and 
cyclophosphamide 500 mg/m2 (FEC) or to 3 cycles of 
the same regimen followed by 3 cycles of 100 mg/m2 of 
docetaxel (D) (Roché et al 2006). After a median follow-up 
of 60 months, switching over to docetaxel after 3 cycles 
of FEC resulted in an improvement in 5-year disease-free 
(78.4% vs 73.2%; p = 0.01) and overall survival (90.7% 
vs 86.7%; p = 0.02). The rate of distant metastasis was 
lower in patients who received FEC-D (18.1% vs 14.9%). 
Similar to the BCIRG study, among the patients with 
1–3 positive nodes there was a signiﬁ  cant reduction in the 
Figure 1 Adjuvant therapy for node positive breast cancer. Adapted from Martin et al (2005).
Abbreviations: FAC, ﬂ  uorouracil, doxorubicin, and cyclophosphamide; TAC, docetaxel, doxorubicin, and cyclophosphamide.
Table 1 Phase III trials of docetaxel as adjuvant therapy in patients with node-positive breast cancer
Study Regimen Number of patients Disease-free survival Overall survival
BCIRG 001 TAC vs FAC 1,491 75% vs 68% p = 0.001 87% vs 81% p = 0.008
FNCLCC PACS 01 FEC X 3→docetaxel × 3 vs FEC X 6 1,999 78% vs 74% p = 0.041 91% vs 87% p = 0.05
BIG 2-098 A→T + AT vs A + AC 2,887 HR 0.86 p = 0.051 HR 0.92 p = 0.34
Abbreviations: HR, hazard ratio; A, doxorubicin; AC, doxorubicin and cyclophosphamide; AT, adriamycin, docetaxel; FAC, ﬂ  uorouracil, doxorubicin, and cyclophosphamide; 
TAC, docetaxel, doxorubicin, and cyclophosphamide; FEC, ﬂ  uorouracil, epirubicin, and cyclophosphamide.
1491 women with node positive breast cancer underwent
randomization post surgery 
745 women randomized to TAC 746 women randomized to FAC 
1 woman in the TAC group and 10 
assigned to receive FAC did not
receive treatment for the following 
reasons: 8 withdrew consent, 1 was 
lost to follow up, and 2 did not 
receive treatment for other reasons
TAC group: 144 (19.3%) 
relapsed with breast 
cancer
FAC group: 197 (26.4%) 
relapsed with breast 
cancerTherapeutics and Clinical Risk Management 2008:4(2) 422
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risk of relapse with FEC→D compared with FEC alone 
(p = 0.04). Similar beneﬁ  ts were not observed in women 
with more than 3 positive lymph nodes. Interestingly, the 
beneﬁ  t in DFS was more apparent in women age 50 years 
or older (p = 0.001) than in younger women (p = 0.65). 
The addition of docetaxel was associated with a higher 
rate of febrile neutropenia, but the overall incidence of 
grade 3 or 4 neutropenia in cycles 4–6 was higher in the 
FEC group (20.2% vs 10.9 %) The use of growth factors 
was signiﬁ  cantly increased in patients receiving 6 cycles 
of FEC (p  0.001) Treatment with FEC-D was associated 
with signiﬁ  cantly fewer cardiac events.
Safety data from ongoing studies have been reported. 
The data on efﬁ  cacy are awaited. The BCIRG 005 study 
randomized 3298 patients with node-positive breast cancer to 
either 6 cycles of docetaxel (75 g/m2), doxorubicin, and cyclo-
phosphamide (TAC) or 4 cycles of doxorubicin and cyclo-
phosphamide, followed by docetaxel (T) (100 mg/m2). Both 
regimes were administered every 3 weeks (Eiermann et al 
2005). Patients were given prophylactic ciproﬂ  oxacin and 
G-CSF was administered at the time of febrile neutropenia. 
There was an increased incidence of febrile neutropenia in 
the TAC group (17.9% vs 8.5%), and more neurotoxicities 
and myalgias in the AC followed by T arm.
In the phase III PACS 04 trial, patients were randomized 
to receive 6 cycles of FEC 100 or 6 cycles of epirubicin 
and docetaxel (75 mg/m2) (ET). The patients in the ET arm 
had an increased incidence of febrile neutropenia (31% vs 
10.7%) while there was a signiﬁ  cant decline in the left ven-
tricular ejection fraction seen in the FEC arm (Spielmann 
et al 2006).
A phase II trial (Piedbois et al 2005) evaluated grade 4 
toxicities of 6 cycles of docetaxel (75 mg/m2), epirubicin 
(75 mg/m2), and cyclophosphamide (500 mg/m2) every 3 
weeks (control group) or 4 cycles of epirubicin (100 mg/m2) 
and cyclophosphamide (600 mg/m2) followed by 4 cycles of 
docetaxel (100 mg/m2 ) every 2 weeks (arm A) or 4 cycles 
of docetaxel followed by 4 cycles of epirubicin and cyclo-
phosphamide (arm B), in 100 patients with node-positive 
breast cancer. Prophylactic pegﬁ  lgastrim was administered. 
Sixty-one patients were evaluated for toxicity. Grade 3/4 
toxicities of the control arm compared with arm A or arm 
B included neutropenia (38% vs 35% vs 33%), hand foot 
syndrome (0% vs 25% vs 33%), neurotoxicity (0% vs 15% 
vs 6%), and nausea (0% vs 155 vs 6%) respectively. The 
incidence of febrile neutropenia was highest in the control 
group (14% vs 5% vs 0%). These regimens remain to be 
tested in phase III trials.
An ongoing Italian study randomized patients to receive 
either 4 cycles of EC (epirubicin 120 mg/m2 and cyclophos-
phamide 600 mg/m2) Q21 days or 4 cycles of docetaxel 
(100 mg/m2) followed by 4 cycles of EC. Initial data on 
toxicity revealed a higher rate of grade 4 neutropenia and 
febrile neutropenia in the docetaxel arm with an increased 
incidence of grade 3/4 nausea/vomiting in the EC arm 
(Valeria et al 2001).
In summary, studies in node-positive breast cancer with 
docetaxel given concurrently or sequentially with anthra-
cyclines improved disease-free survival. This beneﬁ  t was 
most evident in patients with fewer than 3 positive nodes. 
Prophylactic use of growth factors should be considered 
in patients receiving docetaxel in combination with other 
myelosuppressive chemotherapy.
Docetaxel in studies including both 
node-negative and node-positive 
breast cancer
A number of important studies addressing docetaxel in the 
adjuvant setting have included both node-negative and node-
positive patients. The Eastern Cooperative Oncology Group 
(ECOG) trial E2197 randomized 2952 women to 4 cycles of 
AT (adriamycin 60 mg/m2, docetaxel 60 mg/m2) or 4 cycles of 
AC (adriamycin 60 mg/m2, cyclophosphamide 600 mg/m2), 
administered every 3 weeks for 4 cycles. Thirty-ﬁ  ve percent 
of the patients were lymph node-positive. After a median 
follow-up of 53 months, DFS was identical (87%) in both 
groups of patients. The incidence of febrile neutropenia 
was higher with AT (19%) than with AC (6%). There were 
3 treatment related-deaths in the AT arm. The difference in 
efﬁ  cacy could be attributed to the lower dose of docetaxel 
and fewer node-positive patients in this ECOG trial.
Jones et al (2006) randomized 1601 patients with stage 
I to III operable invasive breast cancer to 4 cycles of AC 
(60 mg/m2 and 600 mg/m2 respectively) or TC (75 mg/m2 
and 600 mg/m2 respectively), administered every 3 weeks 
in the adjuvant setting. The 5-year DFS rate was superior 
for TC than AC (86% vs 80%, p = 0.15). The patients in 
the AC arm experienced more grade 1 to 4 nausea and 
vomiting (p  0.01), whereas more fever and neutropenia 
was observed with TC (5%) vs AC (2.5%, p = 0.07). In the 
AC group, 1 patient died form congestive heart failure and 1 
patient in the TC group died of sepsis and neutropenia. In a 
subgroup analysis, both node-negative (TC = 239, AC = 248) 
and node-positive (TC = 267, AC = 262) patients seemed to 
favor the TC arm. The HR for node-negative patients was 
0.73 and for the node-positive patients was 0.67, but this Therapeutics and Clinical Risk Management 2008:4(2) 423
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difference was statistically signiﬁ  cant only in patients with 
node-positive disease (p  0.05). The study was not powered 
to detect differences in subgroups.
The North American Breast Cancer Intergroup Trial 
E1199 compared the effectiveness of adjuvant paclitaxel with 
docetaxel, and the effectiveness of 3-weekly with weekly 
adjuvant taxane therapy in 4988 patients with operable breast 
cancer. Patients received 4 cycles of AC (60 mg/m2 and 
600 mg/m2 respectively) every 3 weeks, followed by either: 
paclitaxel 175 mg/m2 every 3 weeks × 4, paclitaxel 80 mg/m2 
weekly × 12, docetaxel 100 mg/m2 every 3 weeks × 4, or 
docetaxel 35 mg/m2 weekly × 12. Most patients (88%) had 
lymph node-positive disease. After a median follow-up of 
46.5 months, there were no signiﬁ  cant differences in HR 
comparing taxane (0.985; p = 0.83) or schedule (1.043; 
p = 0.54) for DFS. In an exploratory analysis, weekly 
paclitaxel was found to have superior DFS compared with 
3-weekly paclitaxel (HR 1.20, p  0.06). The docetaxel arms 
did not differ signiﬁ  cantly from 3-weekly paclitaxel but had 
more Grade III and IV hematological toxicities.
Combinations with trastuzumab
Trastuzumab is a humanized monoclonal antibody against 
the HER2 protein, which is overexpressed in 15%–25% of 
breast carcinomas. The role of trastuzumab is established in 
metastatic breast cancer where it improves survival when 
administered with chemotherapy (Slamon et al 2001). This 
beneﬁ  t extended to the adjuvant setting with 2 large phase 
III randomized placebo-controlled trials demonstrating a 
signiﬁ  cant improvement in DFS with the addition of trastu-
zumab to conventional chemotherapy (Piccart-Gebhart et al 
2005; Romond et al 2005).
Interestingly, data obtained from in vitro experiments 
show that docetaxel exhibits synergistic effects against 
breast cancer cells when administered with trastuzumab, in 
contrast to the additive effects it exhibits when given with 
paclitaxel.
In early trials of trastuzumab with chemotherapy, 27% of 
patients treated concurrently with trastuzumab and anthra-
cyclines, 13% with trastuzumab and paclitaxel, and 5% with 
trastuzumab alone had cardiotoxic events (Slamon et al 2001). 
To overcome the risk of cardiotoxicity, the BCIRG 006 trial 
randomized patients into 3 arms: comparing doxorubicin 
and cyclophosphamide followed by docetaxel (AC→T) with 
doxorubicin and cyclophosphamide followed by docetaxel 
and trastuzumab (AC→TH) with docetaxel, carboplatin, 
and trastuzumab (TCH). The combination of docetaxel and 
trastuzumab was well tolerated. After a median follow-up of 
36 months, both AC→TH and TCH signiﬁ  cantly improved 
the DFS and OS over the control (Slamon et al 2005).
A prospectively designed subgroup analysis of the 
BCIRG 001 trial showed that Her 2-neu positive patients 
treated with TAC had a signiﬁ  cant reduction in risk (0.60, 
CI 0.41–0.88) compared with FAC (Trudeau et al 2005). 
To date, there is insufﬁ  cient evidence to conclude that HER 
2-neu positive breast cancer patients derive superior beneﬁ  t 
from this combination and it still remains to be tested in 
well-designed randomized clinical trials.
Conclusions
Adjuvant trials with docetaxel have demonstrated a signiﬁ  -
cant reduction in recurrence and longer disease-free interval 
in patients with node-positive breast cancer (Martin et al 
2005). The survival beneﬁ  t was more apparent in patients 
with fewer than 3 axillary lymph nodes and in women older 
than 50 years of age (Martin et al 2005; Roché et al 2006). 
The most common side effect is myelosuppression and 
neutropenic fevers. The incidence of this can be reduced by 
prophylaxis with growth factors. Hypersensitive reactions 
and ﬂ  uid retention are minimized by administration of dexa-
methasone and histamine receptor antagonists.
Addition of trastuzumab to docetaxel appears promis-
ing. Combination of docetaxel with antiangiogeneic agents 
and trastuzumab is currently under investigation. Further 
studies are needed to deﬁ  ne the most effective and safe dos-
ing regimen of docetaxel to maximize beneﬁ  t and reduce 
the incidence of neutropenic complications in patients with 
node-positive breast cancer.
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